AKTS insider filings
Aktis Oncology, Inc. — 37 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-24. Screen AKTS transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 5 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 11 legs across 5 filings by 3 insiders — 120,421 shares, $3,231,412 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
- Largest priced transaction: sale of 30,829 shares @ $27.95 ($861,735) by Czibere Akos, filed 2026-07-10.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Czibere Akos — Chief Medical Officer | 2 | — | 5 legs · 62,500 sh · $1,647,322 | 4 |
| Ron-Bigger Shulamit — Chief Operating Officer | 1 | — | 3 legs · 50,000 sh · $1,387,558 | 2 |
| Herrmann Ken — Director | 2 | — | 3 legs · 7,921 sh · $196,533 | 6 |
Recent insider filings — Aktis Oncology, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-24 | 4 | Czibere Akos — Chief Medical Officer | Option exercise (M): 12,500 @ $4.95 · Sale (S): 5,099 @ $20.19 · Sale (S): 7,401 @ $21.03 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4 | Herrmann Ken — Director | Option exercise (M): 3,506 @ $0.08 · Option exercise (M): 1,350 @ $1.91 · Sale (S): 3,506 @ $24.56 · Sale (S): 1,350 @ $24.56 · Option exercise (M): 3,506 (derivative) @ $0 · Option exercise (M): 1,350 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Herrmann Ken — Director | Option exercise (M): 3,065 @ $0.08 · Sale (S): 3,065 @ $25.21 · Option exercise (M): 3,065 (derivative) @ $0 | EDGAR |
| 2026-07-10 | 4 | Ron-Bigger Shulamit — Chief Operating Officer | Option exercise (M): 50,000 @ $3.66 · Sale (S): 15,800 @ $27.13 · Sale (S): 30,000 @ $27.94 · Sale (S): 4,200 @ $28.75 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-07-10 | 4 | Czibere Akos — Chief Medical Officer | Option exercise (M): 50,000 @ $4.95 · Sale (S): 14,800 @ $27.13 · Sale (S): 30,829 @ $27.95 · Sale (S): 4,371 @ $28.71 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-04-16 | 4 | Gormley Glenn — Director | Grant/award (A): 37,866 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | Foley Todd — Director, 10% owner | Conversion (C): 597,391 · Conversion (C): 2,688,270 · Conversion (C): 716,872 · Purchase (P): 232,870 @ $18 · Conversion (C): 2,272,727 (derivative) @ $0 · Conversion (C): 10,227,273 (derivative) @ $0 · +1 more | EDGAR |
| 2026-01-14 | 4 | MPM BIOVENTURES 2018, L.P. — 10% owner EVNIN LUKE — 10% owner MPM BIOVENTURES 2018 (B), L.P. — 10% owner MPM BioVentures 2018 LLC — 10% owner MPM BioVentures 2018 GP LLC — 10% owner MPM ASSET MANAGEMENT INVESTORS BV2018 LLC — 10% owner MPM ONCOLOGY INNOVATIONS FUND LP — 10% owner MPM Oncology Innovations Fund GP LLC — 10% owner | Conversion (C): 1,314,262 · Conversion (C): 5,914,197 · Conversion (C): 1,577,119 · Purchase (P): 1,112,777 @ $18 · Conversion (C): 5,000,000 (derivative) @ $0 · Conversion (C): 22,500,000 (derivative) @ $0 · +1 more | EDGAR |
| 2026-01-14 | 4 | GADICKE ANSBERT — 10% owner MPM ASSET MANAGEMENT LLC — 10% owner Oncology Impact Private Investment Fund 2, L.P. — 10% owner | Conversion (C): 1,314,262 · Conversion (C): 5,914,197 · Conversion (C): 1,577,119 · Purchase (P): 1,112,777 @ $18 · Conversion (C): 5,000,000 (derivative) @ $0 · Conversion (C): 22,500,000 (derivative) @ $0 · +1 more | EDGAR |
| 2026-01-12 | 4 | Vida Ventures II, LLC — 10% owner VIDA VENTURES II-A, LLC — 10% owner | Conversion (C): 4,859,370 · Purchase (P): 812,455 @ $18 · Conversion (C): 134,842 · Purchase (P): 22,545 @ $18 · Conversion (C): 14,838,250 (derivative) @ $0 · Conversion (C): 411,750 (derivative) @ $0 · +2 more | EDGAR |
| 2026-01-12 | 4 | Segal Lloyd Mitchell — Director | Conversion (C): 19,631 · Conversion (C): 50,000 (derivative) @ $0 · Conversion (C): 24,687 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | EcoR1 Capital, LLC — Director NODELMAN OLEG — Director | Conversion (C): 2,270,879 · Conversion (C): 202,862 · Conversion (C): 128,506 · Purchase (P): 2,077,779 @ $18 · Purchase (P): 144,443 @ $18 · Conversion (C): 9,913,810 (derivative) · +6 more | EDGAR |
| 2026-01-12 | 4 | Kim Helen Susan — Director, 10% owner | Conversion (C): 4,859,370 · Purchase (P): 812,455 @ $18 · Conversion (C): 134,842 · Purchase (P): 22,545 @ $18 · Conversion (C): 14,838,250 (derivative) @ $0 · Conversion (C): 411,750 (derivative) @ $0 · +2 more | EDGAR |
| 2024-01-31 | 4 | Geiss Arthur — Director | Purchase (P): 50,000 @ $0.50 | EDGAR |
| 2024-01-31 | 4 | Aichele David — EVP of Business Development | Purchase (P): 80,000 @ $0.50 | EDGAR |
| 2024-01-31 | 4 | Boller Kenneth — CFO | Purchase (P): 60,000 @ $0.50 | EDGAR |
| 2024-01-31 | 4 | Shealy Jeffrey B. — Chief Executive Officer, Director | Purchase (P): 1,310,000 @ $0.50 | EDGAR |
| 2023-12-20 | 4 | Aichele David — EVP of Business Development | Sale (S): 1,500 @ $0.72 | EDGAR |
| 2023-12-20 | 4 | Boller Kenneth — CFO | Sale (S): 1,200 @ $0.72 | EDGAR |
| 2023-11-22 | 4 | Aichele David — EVP of Business Development | Sale (S): 2,600 @ $0.59 | EDGAR |
| 2023-11-22 | 4 | Boller Kenneth — CFO | Sale (S): 1,700 @ $0.59 | EDGAR |
| 2023-11-08 | 4 | Geiss Arthur — Director | Grant/award (A): 138,333 @ $0 | EDGAR |
| 2023-11-08 | 4 | McMahon Jeffrey — Director | Grant/award (A): 78,250 @ $0 | EDGAR |
| 2023-11-08 | 4 | McGuire James Michael — Director | Grant/award (A): 83,500 @ $0 | EDGAR |
| 2023-11-08 | 4 | Denbaars Steven — Director | Grant/award (A): 38,250 @ $0 · Grant/award (A): 76,500 (derivative) @ $0 | EDGAR |
| 2023-11-08 | 4 | Petock Michelle — Director | Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
| 2023-11-08 | 4 | RUDY SUZANNE B — Director | Grant/award (A): 108,250 @ $0 | EDGAR |
| 2023-11-08 | 4 | NEAL JERRY D — Director | Grant/award (A): 125,750 @ $0 | EDGAR |
| 2023-09-28 | 4 | Shealy Jeffrey B. — Chief Executive Officer, Director | Grant/award (A): 80,000 @ $0 | EDGAR |
| 2023-09-15 | 4 | Aichele David — EVP of Business Development | Grant/award (A): 40,000 @ $0 | EDGAR |
| 2023-09-15 | 4 | Boller Kenneth — CFO | Grant/award (A): 40,000 @ $0 | EDGAR |
| 2023-09-13 | 4 | Boller Kenneth — CFO | Sale (S): 3,900 @ $1.10 | EDGAR |
| 2023-09-13 | 4 | Aichele David — EVP of Business Development | Sale (S): 5,300 @ $1.09 | EDGAR |
| 2023-08-22 | 4 | Denbaars Steven — Director | Sale (S): 7,000 @ $1.83 | EDGAR |
| 2023-03-23 | 4 | Petock Michelle — Director | Grant/award (A): 24,151 @ $0 | EDGAR |
| 2023-03-10 | 4 | McGuire James Michael — Director | Grant/award (A): 2,002 @ $0 | EDGAR |
| 2023-02-14 | 4 | Boller Kenneth — CFO | Sale (S): 800 @ $4.37 | EDGAR |
Recent 8-K events — Aktis Oncology, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-15 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-17 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2024-12-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.03 — Bankruptcy or Receivership 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-12 | 8-K | 8.01 — Other Events | EDGAR |
| 2024-12-02 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AKTS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →